Privo Technologies Marks Key Progress in CLN-004 Trial for PRV211 Treatment in Oral Cancer Patients Privo Technologies successfully completes enrollment for Arm 2 of the CLN-004 trial, achieving primary safety goals without serious adverse events in patients treated with PRV211.

Privo Technologies Marks Key Progress in CLN-004 Trial for PRV211 Treatment in Oral Cancer Patients #United_States #Boston #Privo_Technologies #CLN-004 #PRV211